Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Haemophilus influenzae type b Conjugate Vaccine Inactivated Poliovirus Vaccine IPV Brand Name – Pentacel
What is Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Haemophilus influenzae type b Conjugate Vaccine Inactivated Poliovirus Vaccine IPV
Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Haemophilus influenzae type b Conjugate Vaccine Inactivated Poliovirus Vaccine IPV (Pentacel) is the first FDA-approved pentavalent vaccine for immunization against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b.
The pentavalent vaccine will reduce the number of required injections for protection against diphtheria, tetanus, pertussis, haemophilus influenza type b, and polio.
Pentacel is administered intramuscularly in infants at least 6 weeks of age and children less than 5 years of age.
Four doses constitute a primary immunization course against pertussis, and three doses constitute a primary immunization course against diphtheria, tetanus, H. influenzae type b invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H. influenzae type b invasive disease, and poliomyelitis.
Of note, the 2008 recommended immunization schedule from the Centers for Disease Control calls for an inactivated poliovirus vaccine at 2 months of age, 4 months of age, between 6 and 18 months of age, and at 4—6 years of age.
Consult the current CDC immunization schedule. The FDA approved Pentacel® in June 2008.
Indications
- diphtheria prophylaxis
- Haemophilus influenzae type b prophylaxis
- pertussis prophylaxis
- poliovirus prophylaxis
- tetanus prophylaxis
Side Effects
- aluminum toxicity
- anaphylactic shock
- anaphylactoid reactions
- angioedema
- anorexia
- apnea
- arthralgia
- bronchospasm
- chills
- cyanosis
- diarrhea
- drowsiness
- dyspnea
- encephalopathy
- erythema
- fever
- Guillain-Barre syndrome
- headache
- hemolytic anemia
- hypoesthesia
- hypotension
- hypotonia
- inconsolable crying
- increased intracranial pressure
- injection site reaction
- irritability
- lethargy
- lymphadenopathy
- maculopapular rash
- muscle paralysis
- myelitis
- nausea
- neuritis
- paresthesias
- peripheral neuropathy
- pruritus
- purpura
- rash
- seizures
- syncope
- thrombotic thrombocytopenic purpura (TTP)
- urticaria
- vomiting
- weakness
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- albumin hypersensitivity
- anticoagulant therapy
- breast-feeding
- children
- coagulopathy
- encephalopathy
- fever
- geriatric
- Guillain-Barre syndrome
- hemophilia
- immunosuppression
- infants
- infection
- intraarterial administration
- intravenous administration
- neomycin hypersensitivity
- neonates
- neurological disease
- polymyxin hypersensitivity
- polysorbate 80 hypersensitivity
- pregnancy
- premature neonates
- seizure disorder
- seizures
- shock
- subcutaneous administration
- thrombocytopenia
- vitamin K deficiency
Interactions
- Ocrelizumab
- Siponimod
